Work

Supplementary Figure 4 from Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 240K, Demonstration that CK1alpha or CK2alpha knockdown results in enhanced sensitivity of NSCLC cells to gefitinib treatment, that these knockdowns reduce the expression of the corresponding proteins, that treatment with the CK1� activator pyrvinium pamoate acts synergistically with gefitinib to eliminate NSCLC cells, and specificity of this synergistic cell killing for NSCLC cells following EGFR inhibition

DOI: 10.1158/0008-5472.22391505.v1

Authors: Matias Casás-Selves, Jihye Kim, Zhiyong Zhang, Barbara A. Helfrich, Dexiang Gao, Christopher C. Porter, Hannah A. Scarborough, Paul A. Bunn, Daniel C. Chan, Aik Choon Tan, James DeGregori

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361894724

Cites:

Cited by:

Related to: 10